TrialCancer discovery2024

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

Jessica J Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.